Bedrijfsoverzicht
Burning Rock Biotech Limited is a specialized enterprise focused on the development and commercialization of cancer therapy selection tests, with primary operational activities concentrated in the People's Republic of China and the United States. Operating within the Healthcare sector and specifically the Diagnostics & Research industry, the company leverages its technological capabilities to serve three distinct business segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The market capitalization of the entity stands at $170.60M, reflecting its valuation in the public markets, while the reported annual revenue for the trailing twelve months amounts to $539.57M. Although specific employee count data is not available in the current disclosure, the combination of a substantial market cap and significant revenue generation indicates that Burning Rock Biotech holds a notable position within its niche, possessing the financial scale to sustain operations across multiple geographic and functional domains without reliance on external financing for day-to-day liquidity.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $539.57M, yet this top-line figure masks a net income loss of $-55,346,000 and an EBITDA figure of $-3,458,000, revealing a cost structure where operating expenses and research investments significantly outweigh current profitability. The substantial gap between the $539.57M revenue and the negative net income highlights the capital-intensive nature of the diagnostics business, where high upfront costs for R&D and market expansion currently suppress bottom-line earnings despite strong sales volume. Free cash flow for the period stood at $-41,697,876, indicating that the company is burning through cash reserves to fund its growth initiatives rather than generating excess liquidity for shareholder returns or debt reduction. Despite the negative cash flow, the balance sheet remains robust with $478.39M in cash on hand, which dwarfs the total debt obligation of $43.12M, suggesting a conservative liquidity position capable of weathering prolonged periods of unprofitability. The debt-to-equity ratio of 8.06 suggests a leveraged capital structure relative to equity, yet the sheer volume of cash provides a significant buffer against this debt load. Margins further illustrate the financial dynamics, with a gross margin of 74.7% demonstrating strong pricing power or low cost of goods sold, contrasted sharply by an operating margin of -9.5% and a profit margin of -10.3%, which indicate that overhead and operational inefficiencies are currently eroding gross profits. Return on Equity is recorded at -9.9% and Return on Assets at -4.0%, metrics that reveal the current inability of management to generate returns on the capital base, a common characteristic for biotech firms in early or growth phases where reinvestment outpaces returns. Finally, the current ratio of 2.99 signals strong short-term liquidity, confirming that the company possesses more than double the current assets required to meet its immediate liabilities.
Waarderingsbeoordeling
Valuation multiples present a complex picture for Burning Rock Biotech, with a P/E Ratio (TTM) listed as N/A due to negative earnings, while the Forward P/E stands at -27.32, implying that the market expects earnings to remain negative or for the company to operate at a loss in the near term. The Price to Book ratio is 2.13, indicating that the market values the company at a significant premium over its net asset value, likely driven by intangible assets such as intellectual property and future growth potential rather than tangible book equity. Alternative valuation metrics provide further insight, with a Price to Sales ratio of 0.32 suggesting the stock trades at a fraction of its revenue, while the EV/EBITDA of -354.19 reflects the extreme leverage and lack of earnings power inherent in the current financial structure. The stock has experienced high volatility, trading between a 52-week low of $2.18 and a high of $41.72, with the current price position relative to this range dependent on real-time market data not explicitly defined in the static facts, but the wide spread underscores the speculative nature of the investment. The Beta value of 1.60 indicates that the stock price is significantly more volatile than the broader market, moving with a greater amplitude than the benchmark index, which aligns with the high-risk profile typical of small-cap healthcare biotech firms. These valuation figures collectively suggest that investors are pricing in high-growth expectations that must be realized quickly to justify the current market capitalization of $170.60M.
Growth & Income
Revenue growth for the trailing twelve months is minimal at 0.2%, while earnings growth is marked as N/A due to the company's consistent net losses, implying that the company is prioritizing market share expansion and product development over immediate profitability. As a non-dividend payer with a Dividend Yield of N/A and a Payout Ratio of 0.0%, the company explicitly chooses to retain all earnings to fund its aggressive research and development activities rather than distributing cash to shareholders. This strategy of reinvesting earnings into growth is typical for companies in the Diagnostics & Research industry that require substantial capital expenditure to maintain a competitive edge in cancer therapy selection testing. The overall growth and income profile is characterized by stable but slow revenue expansion and a complete absence of dividend income, reflecting a business model that relies entirely on capital appreciation and operational scaling to create value for investors in the Healthcare sector.